Orchestra BioMed Holdings, Inc..
OBIO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing transformative therapeutic solutions for high-impact diseases. The company primarily focuses on cardiovascular diseases and is involved in the development and commercialization of novel medical devices and thera...Show More
Better Health for All
0
No evidence available to assess Orchestra BioMed Holdings, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic solutions and medical devices.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer financial services to consumers.
2
Consequently, all Key Performance Indicators related to Fair Money & Economic Opportunity, including underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its operations.
3
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles to assess Orchestra BioMed Holdings, Inc. against any of the KPIs for Fair Pay & Worker Respect. While executive compensation data was available for the CEO and other executives, median employee compensation was not provided, preventing the calculation of the CEO-to-median-pay ratio.
1
All other KPIs, including living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, and health insurance coverage, lacked any relevant evidence.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Orchestra BioMed Holdings, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company has a whistleblower policy, effective January 26, 2023, which includes a toll-free hotline and website for anonymous reporting, as well as an Open Door Policy.
1
Employees are required to sign an annual acknowledgment form confirming receipt and understanding of the Code of Business Conduct and Ethics, and the company provides a program of Code awareness, training, and review, including refresher sessions.
2
The Audit Committee oversees investigations related to accounting and internal controls.
3
The company reported one financial restatement due to a reverse recapitalization in accordance with U.S. GAAP, which retroactively restated shares and capital amounts prior to the business combination.
4
A comprehensive anti-corruption policy is in place, effective January 26, 2023, which addresses compliance with the Foreign Corrupt Practices Act and other anti-corruption laws.
5
This policy includes annual training and acknowledgment requirements for employees, directors, officers, and agents, and states that proceeds from loans will not be used in violation of anti-corruption laws.
6
Kind to Animals
0
No information regarding the company's animal welfare practices, animal testing policies, use of animal-derived ingredients, or involvement in animal-free alternatives was found in the provided articles.
1
The articles focus on the company's business model, leadership, product pipeline, and technologies related to medical devices for treating hypertension and artery disease.
2
No War, No Weapons
0
No specific, concrete data points relevant to the 'No War, No Weapons' ethical value were found in the provided articles.
1
is a corporate governance overview without quantitative data.
2
could not be accessed due to a throttling error.
3
is a purchase order agreement and does not contain information related to the company's involvement with arms, defense, or peace initiatives.
Planet-Friendly Business
0
The provided articles do not contain any specific, concrete data points or mentions related to Orchestra BioMed Holdings, Inc.'s performance across any of the 'Planet-Friendly Business' KPIs.
1
For every relevant KPI, the evidence explicitly states 'Not applicable. No specific data found' or 'No mention of X'.
2
Therefore, no KPIs can be scored based on the provided information.
Respect for Cultures & Communities
0
The provided articles for Orchestra BioMed Holdings, Inc. primarily focus on clinical trial results, regulatory approvals, and investor relations. There is no explicit evidence or quantitative data regarding the company's engagement with local or indigenous communities, cultural impact assessments, local employment, grievance mechanisms, cultural preservation investments, or any other metrics related to the 'Respect for Cultures & Communities' ethical value.
1
Therefore, no KPIs under this value can be scored based on the provided information.
Safe & Smart Tech
0
No evidence available to assess Orchestra BioMed Holdings, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding Orchestra BioMed Holdings, Inc.'s performance on waste diversion rates, product recyclability, packaging sustainability, recycled content usage, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management practices, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.
1
While the company's Code of Business Conduct and Ethics mentions a commitment to "reducing waste generation" and "disposing of all waste through safe and responsible methods,"
2
these are statements of intent or policy rather than evidence of implemented initiatives, measurable outcomes, or specific practices.